Trial Will Evaluate Frontline Treatment With Lifileucel in Melanoma
Source: CureToday, June 2023
The TILVANCE-301trial, expected to be completed in 2030, is the latest study of what has been described as one of the “phenomenal discoveries in melanoma.”
The first participant has been randomized in a phase 3 trial evaluating the novel polyclonal tumor-infiltrating lymphocyte (TIL) therapy lifileucel combined with Keytruda (pembrolizumab) against Keytruda alone in the frontline treatment of patients with advanced unresectable or metastatic melanoma, according to a news release from biotechnology company Iovance Biotherapeutics.
The global TILVANCE-301 trial, according to its listing on clinicaltrials.gov, is currently recruiting participants, and will have an estimated enrollment of 670 patients who have received no prior therapies for metastatic disease, with an estimated study completion date of March 1, 2030.